SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, September 15, 20

NEW YORK--(BUSINESS WIRE)--Sep 1, 2026--E*TRADE from Morgan Stanley today released the data from its

Morgan Stanley has lapped every major bank rival in 2026, but a rate spike just rattled the stock and the one price level that would confirm the bull case remains stubbornly out of reach.

A Fox Corp. stockholder has sued the media company and its board in the Delaware Chancery Court, seeking to block a shareholder vote tied to Fox's planned $22 billion acquisition of Roku Inc. until investors receive more information about alleged conflicts involving financial adviser Morgan Stanley.

Goldman Sachs, Morgan Stanley and Citigroup are pressing outside lawyers to cut costs as AI speeds up routine legal work including research.

Eli Lilly and Company will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Ilya Yuffa, Lilly's executive vice president and president of Lilly USA and Global Customer Capabilities, will join a fireside chat at 1:50 p.m. Eastern time. The event will be webcast live and available for replay on Lilly's investor website. This participation highlights Lilly's ongoing commitment to advancing healthcare innovations and communicating with investors about their progress in treating major health challenges like diabetes, obesity, Alzheimer's, immune disorders, and cancer.

MUFG is exploring separate collaborations with BlackRock and Morgan Stanley Investment Management to develop Japanese private credit.

UBS Group reduced their target price on shares of Morgan Stanley Direct Lending Fund from $16.25 to $15.50 and set a "neutral" rating on the stock in a report on Tuesday.